# ARSD

## Overview
The ARSD gene encodes the enzyme arylsulfatase D, a member of the sulfatase family, which is involved in the hydrolysis of sulfate esters. This gene is located on the X chromosome at Xp22.3 and is part of a cluster of sulfatase genes that likely arose from gene duplications in an ancestral pseudoautosomal region (Meroni1996Characterization). Arylsulfatase D is categorized as a lysosomal enzyme, although its specific physiological substrates and functions remain largely unidentified (Parenti1997The; Trojani2012Gene). The ARSD gene produces two isoforms, ARSDa and ARSDb, through alternative splicing, which are expressed in various human tissues (Urbitsch2000Arylsulfatase). Despite the conservation of key catalytic residues, these isoforms have not demonstrated sulfatase activity in vitro using standard assays, suggesting a unique functional role compared to other arylsulfatases (Urbitsch2000Arylsulfatase). The gene's expression and potential involvement in disease, such as its role in breast cancer, highlight its significance as a prognostic marker and potential therapeutic target (Lin2021ARSD).

## Structure
The ARSD gene encodes two protein isoforms, ARSDa and ARSDb, which are part of the arylsulfatase family. These isoforms are characterized by their ability to hydrolyze sulfate esters, although they do not show activity in the 4-MUS assay (Urbitsch2000Arylsulfatase). The ARSD proteins have a conserved N-terminal sequence essential for sulfatase function, including a catalytically essential cysteine residue. Both isoforms contain a unique HSV tripeptide in the N-terminal sequence, differing from the YPV tripeptide found in other arylsulfatases. This tripeptide is part of a hinge region between two helical domains, one of which includes the essential cysteine (Urbitsch2000Arylsulfatase).

The ARSDa isoform is a putative protein of 594 amino acids, while ARSDb is 382 amino acids long. The N-terminal 333 amino acids include a highly conserved sulfatase activity domain, with a conserved cysteine that undergoes conversion to 2-amino-3-oxopropionic acid, a feature common to all eukaryotic sulfatases (Urbitsch2000Arylsulfatase). Despite the structural similarities to other arylsulfatases, the ARSD proteins did not catalyze the cleavage of the sulfate bond of the 4-MUS substrate efficiently (Urbitsch2000Arylsulfatase).

## Function
The ARSD gene encodes the arylsulfatase D enzyme, which is part of the sulfatase family involved in the hydrolysis of sulfate esters. These enzymes are crucial for the metabolism of sulfated molecules, impacting cellular processes such as hormone regulation, cell signaling, and the degradation of glycosaminoglycans (Parenti1997The). ARSD is located on the X chromosome at Xp22.3 and is part of a cluster of sulfatase genes that likely originated from gene duplications in an ancestral pseudoautosomal region (Meroni1996Characterization).

The ARSD enzyme is a lysosomal enzyme, although its specific physiological substrates and functions in healthy human cells remain largely unidentified (Parenti1997The; Trojani2012Gene). Despite the conservation of key catalytic residues, ARSD proteins have not demonstrated sulfatase activity in vitro using standard assays, suggesting that their function may differ from other arylsulfatases (Urbitsch2000Arylsulfatase). The ARSD gene produces two isoforms, ARSDa and ARSDb, through alternative splicing, which are expressed in various human tissues, although their precise roles and activities remain unclear (Urbitsch2000Arylsulfatase).

## Clinical Significance
The ARSD gene, located on the X chromosome at Xp22.3, is part of a cluster of sulfatase genes that includes ARSE and ARSF. While ARSD itself has not been directly linked to specific diseases, it is part of a region associated with conditions such as chondrodysplasia punctata (CDPX) and multiple sulfatase deficiency (MSD) (Franco1995A). The gene is known to escape X chromosome inactivation, which may contribute to its expression patterns and potential involvement in disease (Franco1995A).

In the context of breast cancer, ARSD expression is significantly higher in luminal subtype breast cancer cells compared to triple-negative breast cancer (TNBC) cells. Its overexpression has been shown to inhibit proliferation and migration of breast cancer cells by activating the Hippo/YAP pathway, suggesting a tumor suppressor role (Lin2021ARSD). The gene's expression is regulated by transcription factors such as ERα, FOXA1, and GATA3, and is influenced by epigenetic modifications, including DNA methylation and histone modifications (Lin2021ARSD). These findings indicate that ARSD may serve as a prognostic marker and potential therapeutic target in breast cancer (Lin2021ARSD).


## References


[1. (Meroni1996Characterization) G Meroni. Characterization of a cluster of sulfatase genes on xp22.3 suggests gene duplications in an ancestral pseudoautosomal region. Human Molecular Genetics, 5(4):423–431, April 1996. URL: http://dx.doi.org/10.1093/hmg/5.4.423, doi:10.1093/hmg/5.4.423. This article has 41 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/5.4.423)

[2. (Urbitsch2000Arylsulfatase) Peter Urbitsch, Manfred J. Salzer, Peter Hirschmann, and Peter H. Vogt. Arylsulfatase d gene in xp22.3 encodes two protein isoforms. DNA and Cell Biology, 19(12):765–773, December 2000. URL: http://dx.doi.org/10.1089/104454900750058125, doi:10.1089/104454900750058125. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1089/104454900750058125)

[3. (Trojani2012Gene) Alessandra Trojani, Barbara Di Camillo, Alessandra Tedeschi, Milena Lodola, Simona Montesano, Francesca Ricci, Eleonora Vismara, Antonino Greco, Silvio Veronese, Aldo Orlacchio, Sabata Martino, Chiara Colombo, Mariangela Mura, Michele Nichelatti, Anna Colosimo, Barbara Scarpati, Marco Montillo, and Enrica Morra. Gene expression profiling identifies arsd as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia. Cancer Biomarkers, 11(1):15–28, July 2012. URL: http://dx.doi.org/10.3233/cbm-2012-0259, doi:10.3233/cbm-2012-0259. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.3233/cbm-2012-0259)

[4. (Parenti1997The) Giancarlo Parenti, Germana Meroni, and Andrea Ballabio. The sulfatase gene family. Current Opinion in Genetics &amp; Development, 7(3):386–391, June 1997. URL: http://dx.doi.org/10.1016/s0959-437x(97)80153-0, doi:10.1016/s0959-437x(97)80153-0. This article has 136 citations.](https://doi.org/10.1016/s0959-437x(97)80153-0)

[5. (Lin2021ARSD) Yun Lin, Chun Li, Wei Xiong, Liping Fan, Hongchao Pan, and Yaochen Li. Arsd, a novel erα downstream target gene, inhibits proliferation and migration of breast cancer cells via activating hippo/yap pathway. Cell Death &amp; Disease, November 2021. URL: http://dx.doi.org/10.1038/s41419-021-04338-8, doi:10.1038/s41419-021-04338-8. This article has 10 citations.](https://doi.org/10.1038/s41419-021-04338-8)

[6. (Franco1995A) Brunella Franco, Germana Meroni, Giancarlo Parenti, Jacqueline Levilliers, Loris Bernard, Marinella Gebbia, Liza Cox, Pierre Maroteaux, Leslie Sheffield, Gudrun A Rappold, Generoso Andria, Christine Petit, and Andrea Ballabio. A cluster of sulfatase genes on xp22.3: mutations in chondrodysplasia punctata (cdpx) and implications for warfarin embryopathy. Cell, 81(1):15–25, April 1995. URL: http://dx.doi.org/10.1016/0092-8674(95)90367-4, doi:10.1016/0092-8674(95)90367-4. This article has 242 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/0092-8674(95)90367-4)